TY  - JOUR
AU  - Lanzafame, Helena
AU  - Mavroeidi, Ilektra A
AU  - Pabst, Kim M
AU  - Fragoso Costa, Pedro
AU  - Schuler, Martin
AU  - Bauer, Sebastian
AU  - Kurth, Jens
AU  - Heuschkel, Martin
AU  - Siveke, Jens T
AU  - Herrmann, Ken
AU  - Kostbade, Karina
AU  - Kersting, David
AU  - Leyser, Stephan
AU  - Fröhling, Stefan
AU  - Heilig, Christoph E
AU  - Hamacher, Rainer
AU  - Fendler, Wolfgang P
TI  - 90Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis.
JO  - Journal of nuclear medicine
VL  - nn
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2026-00406
SP  - nn
PY  - 2026
N1  - epub
AB  - Fibroblast activation protein (FAP) is highly expressed in many cancers, especially sarcomas, and represents a promising theranostic target. We present an updated retrospective analysis of 90Y-FAP inhibitor (FAPI)-46 treatment in patients with sarcoma or other solid tumors. Methods: We performed monocentric analysis of patients with progressive sarcoma or metastatic cancer who were eligible for 90Y-FAPI-46 therapy after approved treatments had been exhausted and who showed high FAP expression (SUVmax, ≥10 in over 50
KW  - 90Y-FAPI-46 (Other)
KW  - radiopharmaceutical therapy (Other)
KW  - sarcomas (Other)
KW  - theranostics (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41714122
DO  - DOI:10.2967/jnumed.125.271135
UR  - https://inrepo02.dkfz.de/record/309980
ER  -